2型糖尿病合并非酒精性脂肪性肝病患者NLR和PLR变化及其临床意义探讨*

doi:10.3969/j.issn.1672-5069.2023.06.012

Abstract

Abstract: Objective The study was conducted to assess the prediction of non-alcoholic fatty liver diseases (NAFLD) in patients with type 2 diabetes mellitus (T2DM) by neutrophil-to-lymphocyte ratio(NLR) and platelet-to-lymphocyte ratio(PLR) . Methods 110 patients with T2DM and 121 patients with T2DM and NAFLD were included in the Department of Endocrinology, Second Provincial People's Hospital between January 2021 and October 2022, and the NAFLD was proven by ultrasonography. The blood routine was checked-up. The risk factors of T2DM with NAFLD were assessed by multivariate Logistic analysis, and predictive efficacy was evaluated by ROC curve. Results The body mass index in patients with T2DM and concomitant NAFLD was (25.4±3.5)kg/m², much greater than [(23.2±3.1)kg/m², P<0.05], while the course of disease was 5.0(2.0, 8.0)yr, significantly shorter than [8.0(3.0, 13.0)yr, P<0.05] in patients with T2DM; serum alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase, uric acid, triglyceride and total cholesterol levels in patients with T2DM and NAFLD were all significantly greater than in patients with T2DM, while serum high density lipoprotein cholesterol level was much lower than in patients with T2DM (P＜0.05); the blood lymphocyte count in patients with T2DM and NAFLD was (1.7±0.4)×10⁹/L, much lower than [(2.2±0.6)×10⁹/L, P<0.05], while the NLR and PLR were (2.4(1.8, 3.2)) and (126.1(93.3, 157.8)), both significantly greater than [1.5(1.2, 2.3) and 89.6(66.9, 116.5), respectively, P<0.05] in patients with T2DM; the Logistic analysis showed that the BMI, NLR and PLR were the risk factors for coincidence of NAFLD in patients with T2DM (P＜0.05); the ROC analysis demonstrated that the sensitivities and the specificities by NLR and PLR in prediction of NAFLD in patients with T2DM were 64.5% and 75.0%, and 71.9% and 65.4%, respectively. Conclusion The surveillance of NLR and PLR, easily accessible, in patients with T2DM might help screen preliminarily NAFLD, and warrants further clinical investigation.

Key words: Non-alcoholic fatty liver diseases, Type 2 diabetes mellitus, Neutrophil-to-lymphocyte ratio, Platelet-to-lymphocyte ratio, Diagnosis

Ding Xiaojie, Zhang Yongming, Song Haiyan, et al. Prediction of NAFLD in patients with type 2 diabetes mellitus by NLR and PLR: A preliminary study[J]. Journal of Practical Hepatology, 2023, 26(6): 815-818.

References

[1] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018年更新版).实用肝脏病杂志,2018,21(2):177-186.
[2] Younossi ZM. Non-alcoholic fatty liver disease–A global public health perspective. J Hepatol,2019,70(3):531-544.
[3] Adams LA, Anstee QM, Tilg H, et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut,2017,66(66):1138-1153.
[4] 刘傲雪,周翔海,张秀英,等.非酒精性脂肪肝的危险因素讨论.中国临床医生杂志,2021,49(2):165-169.
[5] Cupp MA, Cariolou M, Tzoulaki I, et al. Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies. BMC Med,2020,18(1):360.
[6] Gong P, Liu Y, Chen G, et al. The association of neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, and lymphocyte to monocyte ration with post-thrombolysis early neurological outcomes in patients with acute ischemic stroke. J Neuroinflammation,2021,18(1):51.
[7] Diem S, Schmid S, Krapf M, et al. Neutrophil-to-lymphocyte ratio(NLR) and platelet-to-lymphocyte ratio(PLR) as prognostic markers in patients with non-small cell lung cancer(NSCLC) treated with nivolumab. Lung Cancer,2017,111:176-181.
[8] Balta S, Ozturk C. The platelet-lymphocyte ratio: A simple, inexpensive and rapid prognostic marker for cardiovascular events. Platelets,2015,26(7):680-681.
[9] Karakaya S,Altay M,Kaplan EF,et al. The neutrophil-lymphocyte ratio and its relationship with insulin resistance in obesity. Turk J Med Sci,2019,49(1):245-248.
[10] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版).中华糖尿病杂志,2021,13(4):317-411.
[11] Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology,1998,114(4):842-845.
[12] Fang YL, Chen H, Wang CL, et al. Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From "two hit theory" to "multiple hit model".World J Gastroenterol,2018,4(27):2974-2983.
[13] Hu M, Phan F, Bourron O, et al.Steatosis and NASH in type 2 diabetes.Biochimie,2017,143:37-41.
[14] Chacko KR,Reinus J.Extrahepatic complications of nonalcoholic fatty liver disease.Clin Liver Dis,2016,20(2):387-401.
[15] Younossi Z, Tacke F, Arrese M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.Hepatology,2019,69(6):2672-2682.
[16] Paradis V, Perlemuter G, Bonvoust F, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology, 2001,34(4):738-744.
[17] Kahraman NK, Cuneyt C, Kocak FE, et al. Predictive value of neutrophil to lymphocyte ratio in the severity of non-alcoholic fatty liver disease among type 2 diabetes patients. Acta Gastro Enterologica Belgica,2016,79(3):295-300.
[18] 吴仪伟,武攸,崔晓艳,陈琰. PLR、NLR与T2DM合并代谢相关脂肪性肝病肝纤维化的关系. 临床与病理杂志,2022,42(7):1615-1621.
[19] Elgazar Carmon V, Rudich A, Hadad N, et al. Neutrophils transiently infiltrate intra-abdominal fat early in the course of high-fat feeding. J Lipid Res,2008,49(9):1894-1903.
[20] Zimmermann E, Anty R, Tordjman J, et al. C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients. J Hepatol,2011,55(3):660-665.

Prediction of NAFLD in patients with type 2 diabetes mellitus by NLR and PLR: A preliminary study

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zeng Jing, Fan Jiangao. Natural history of metabolic dysfunction-associated fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(6): 769-772.
[2]	Zhou Jiying, Xie Yuehong, Yu Cuixia. Decreased biochemical response to entecavir anti-viral therapy in patients with chronic hepatitis B and concomitant non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(6): 793-796.
[3]	Shao Xiaoru, Zhou Xiao, Ge Yingying. Diagnosis of coronary atherosclerotic heart disease in patients with nonalcoholic fatty liver disease by CCTA and¹⁸F-FDG intake [J]. Journal of Practical Hepatology, 2023, 26(6): 811-814.
[4]	Yan Daobo, Zhu Haichao, Shan Haixia. Assessment of significant liver fibrosis by transient ultrasound elastography and APRI combination in patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2023, 26(6): 831-834.
[5]	Tian Yu, Chen Yan, Cao Jiafei, et al. Changes of urine U-mAl, peripheral blood NLR and serum NGAL level in patients with cirrhosis and complicated hepatorenal syndrome [J]. Journal of Practical Hepatology, 2023, 26(6): 859-862.
[6]	Liu Huan, Chen Peng, Kuai Wentao, et al. Diagnostic performance of liver stiffness measurement, platelet / spleen thickness ratio and splenic vein diameter in predicting esophageal varices in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2023, 26(6): 867-870.
[7]	He Meinian, Zhao Sijia, Tian Zhichao, et al. Ultrasound semi-quantitative score and elastography in the diagnosis of early liver cirrhosis in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(6): 871-874.
[8]	Mo Chunming, Huang Dejia, Wei Huizhang, et al. Predictive efficacy of serum IL-33 and procalcitonin levels for bacterial infection in primary liver cancer patients with fever after TACE [J]. Journal of Practical Hepatology, 2023, 26(6): 887-890.
[9]	Zhou Li, Ding Yunqing, Yuan Fengying, et al. Diagnostic performance of contrast-enhanced ultrasound in determining qualitatively intrahepatic space-occupying lesions in patients with hepatitis B liver cirrhosis [J]. Journal of Practical Hepatology, 2023, 26(6): 903-906.
[10]	Zhang Rui, Shi Qianqian, Wang Zhongqiu. Clinical efficacy of DCE-MRI, DWI and MRCP in the diagnosis of patients with extrahepatic cholangiocarcinoma [J]. Journal of Practical Hepatology, 2023, 26(6): 923-926.
[11]	Huang Baisheng, Ou Lanxin, Zhang Yinjie, et al. Diagnostic performance of FibroScan and GPR, APRI and FIB-4 for liver fibrosis evaluation in patients with chronic hepatitis B virus infection without serum alanine aminotransferase elevation [J]. Journal of Practical Hepatology, 2023, 26(5): 618-621.
[12]	Hao Anhua, Du Zhongcai, Zhou Lin, et al. Changes of liver stiffness measurement and S index in patients with chronic hepatitis B and their performance in evaluating liver fibrosis [J]. Journal of Practical Hepatology, 2023, 26(5): 630-633.
[13]	Liu Aihua, Fu Jian, Chen Xiaohong. Predicting performance of liver stiffness measurement and GGT/PLT ratio combination in judging liver fibrosis in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(5): 634-637.
[14]	Wu Fei, Guo Wen, Zhang Qun. Skeletal muscle mass changes in patients with non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(5): 646-649.
[15]	Cai Xin, Xin Chunhong, Niu Hongkai, et al. Changes of serum HIF-1α, Chemerin and adiponectin levels in patients with metabolic-associated fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(5): 654-657.